全球乳腺病变引导系统市场 – 行业趋势及 2029 年预测

乳腺病变引导系统市场分析及规模

预计全球乳腺病变引导系统市场将在预测期内出现显著增长。全球每年诊断出的乳腺癌中，有三分之一是隐性乳腺癌，随着筛查项目越来越普遍，MRI 等更先进的检查方法能够检测到更多临床潜在病变，这一比例还将上升。这是一种安全、准确的非手术方法，可用于诊断乳腺图像中的可疑异常发现，对于制定正确的决策（包括治疗计划）至关重要。

Data Bridge Market Research 分析了 2022-2029 年预测期内全球乳腺病变引导系统市场的增长率。在上述预测期内，全球乳腺病变引导系统市场的预期复合年增长率约为 5.50%。2021 年市场价值为 2.5 亿美元，到 2029 年将增长至 3.8367 亿美元。除了市场价值、增长率、细分市场、地理覆盖范围、市场参与者和市场情景等市场洞察外，Data Bridge Market Research 团队策划的市场报告还包括深入的专家分析、患者流行病学、渠道分析、定价分析和监管框架。

乳腺病变引导系统市场范围和细分

Market Definition

Cardiac disease is often overlooked on cardiac CT. However, the soft tissue function of the multi-detector CT is sufficient for reliable diagnosis. Breast lesions or injuries are abnormal changes in breast tissue caused by the disease or injury, and breast lesion locating procedures are used to detect, diagnose, and treat diseases or injuries associated with breast tissue. Appropriate guidance systems will lead to the growth of the market.

Global Breast Lesion Guidance Systems Market Dynamics

Drivers

• Increased Prevalence of Breast Cancer

Breast cancer is among the most common diseases affecting women in developed and developing countries. According to the American Cancer Society, breast cancer is the second leading cause of cancer related deaths in women across the globe. Globally, there has been significant growth in the number of breast cancer cases. This can majorly be attributed to changing lifestyles, the increasing use of oral contraceptives, and the growing number of women undergoing cosmetic surgeries, such as breast enhancement.

•  Increased Elderly Population

With age, the risk of developing breast cancer increases. With aging, pluripotent progenitor cells (a type of adult stem cell at the root of many breast cancers) increase, lining breast lactating lumen cells, and reducing the number of myoepithelial cells that function as tumor suppressors. According to the American Cancer Society, about one-eighth of invasive breast cancers occur in women under the age of 45. In contrast, women over the age of 55 develop about two-thirds of invasive breast cancers.

Opportunities

• Funding For Research and clinical activities

Increasing funding for R&D activities for the treatment of oncological diseases by various regulators and some state governments is also expected to boost the growth of the global laboratory development testing market.

• Emerging Economy

Emerging markets such as India, China, Brazil, South Korea, Turkey, Russia and South Africa offer significant growth opportunities for key players operating in the breast lesion guidance market. The large population base of India and China in particular provide a sustainable market for medical and surgical devices as a whole. Emerging market governments are also investing heavily in the development and modernization of healthcare infrastructure. For instance, according to OECD data, China's health care costs in 2020 was $ 810.8 per person. Similarly, Brazil spent about 9.5% of its GDP on health care in 2020, according to health care and financial data. The Brazilian Ministry of Health and several non-governmental agencies have also made efforts to improve early detection in the country and promote breast cancer screening and education.

Restraints/Challenges

• Lack of skilled oncologists

Breast cancer surgery and lesion locating procedures are performed by experienced professionals to achieve better results. These surgeries are considered to be at higher risk than other surgeries due to various challenges such as tumor localization, risk of removal of healthy tissue, lymphedema, and seroma. Similarly, the use of radioactive substances may increase the risk of patients developing radiation-induced cancer. Radiation exposure has several short-term and long-term side effects, usually occurring within 6 months or 1 year of exposure. The most common side effects after radiation exposure include mild pain and discomfort around the breast, skin damage, swelling and inflammation of the breast and surrounding tissues, hair loss on the flanks and breasts, and fatigue. Radiation exposure can also damage nerves in the arms, hands, and chest. To mitigate these risks, the localization procedure requires trained operators and radiologists who must go through a certification process to perform localization of breast lesions.

• Uncertainty in regulatory approval procedures

Regulatory authorities such as the U.S. FDA need comprehensive clinical data to demonstrate the clinical safety and efficacy of approved products. Due to the stringent regulatory requirements for product approval, market players in methods of locating breast lesions (especially radioisotope locating) are nuclear regulated by the Nuclear Regulatory Commission to ensure the safe use of radioactive seeds. You need to get approval for. This approval process is so long and capital intensive that it is difficult for small manufacturers and companies with limited budgets to compete in this market.

本乳腺病变引导系统市场报告详细介绍了最新发展、贸易法规、进出口分析、生产分析、价值链优化、市场份额、国内和本地市场参与者的影响，分析了新兴收入领域的机会、市场法规的变化、战略市场增长分析、市场规模、类别市场增长、应用领域和主导地位、产品批准、产品发布、地域扩展、市场技术创新。如需了解有关乳腺病变引导系统市场的更多信息，请联系 Data Bridge Market Research 获取分析师简报，我们的团队将帮助您做出明智的市场决策，实现市场增长。

COVID-19 对全球乳腺病变引导系统市场的影响

考虑到目前的情况，COVID-19 已造成前所未有的全球公共卫生危机，几乎影响到所有企业，其长期影响预计将在预测期内对行业增长产生影响。

COVID19 疫情对全球所有非 COVID19 疾病的诊断和治疗程序产生了严重影响。这也影响了乳腺病变定位方法市场，因为 COVID19 对患有疫情相关阻塞和合并症的人的不利影响大大减少了医院、诊所和诊断中心的就诊人数。为了应对 COVID 19，许多国家已暂停乳房筛查计划。例如，在加拿大、荷兰、德国、意大利、英国和澳大利亚，国家筛查计划已完全暂停一至六个月。因此，虽然研究市场受到了 COVID 19 疫情的影响，但随着预测期内疫苗接种的持续和 COVID 19 病例数量的减少，研究市场将恢复其潜力。

全球乳腺病变引导系统市场范围

全球乳腺病变引导系统市场根据类型、用途和最终用户进行细分。这些细分市场之间的增长情况将帮助您分析行业中增长缓慢的细分市场，并为用户提供有价值的市场概览和市场洞察，帮助他们做出战略决策，确定核心市场应用。

类型

• 金属丝
• 放射性同位素
• 卷
• 限制性食管鳞状细胞癌
• 磁的
• 电磁定位

用法

• 乳房活检
• 乳房肿瘤切除术

终端用户

• 选择标准
• 替换趋势

全球乳腺病变引导系统市场区域分析/见解

对乳腺病变引导系统市场进行了分析，并按国家、类型、用途和最终用户提供了市场规模洞察和趋势。

乳腺病变引导系统市场报告涉及的主要国家 有：北美洲的美国、加拿大和墨西哥、欧洲的德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、西班牙、土耳其、欧洲其他地区、亚太地区 (APAC) 的中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾、亚太地区 (APAC) 的其他地区、中东和非洲 (MEA) 的其他地区、南美洲的巴西、阿根廷和南美洲其他地区。

近年来，北美占据乳腺病变引导系统市场的主导地位，预计在预测期内也将呈现类似的趋势，这是因为北美乳腺癌病例数量众多，主要再加上强大的医疗基础设施和乳房的存在。

由于医疗保健基础设施的改善、政府对乳腺癌研究的资助增加以及亚太地区多个国家对早期发现乳腺癌重要性的认识迅速提高，预计亚太地区在 2022 年至 2029 年的预测期内将以显著的增长率增长。

报告的国家部分还提供了影响市场当前和未来趋势的各个市场影响因素和国内市场监管变化。此外，在提供国家数据预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈竞争或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。   

竞争格局和全球乳腺病变引导系统市场份额分析

乳腺病变引导系统市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对乳腺病变引导系统市场的关注有关。

乳腺病变引导系统市场的主要参与者包括：

• BD（美国）
• CR Bard, Inc.（美国）
• Devicor Medical Products Inc.（美国）
• Hologic Inc.（美国）
• Merit Medical Systems（美国）
• Leica Biosystems Nussloch GmbH（美国）
• Argon Medical Devices（美国）
• Laurane Medical LLC（法国）
• Endomagnetics Ltd.（英国）
• Intramedical Imaging, LLC（美国）
• Isoaid（美国）
• Surgiceye GmbH (德国)
• Ranfac Corp.（美国）
• 美人鱼医疗集团（丹麦）
• Izi Medical Products, LLC（美国）
• Matek Medikal（土耳其）
• Tsunami Medical Srl（意大利）
• BPB Medica（意大利）
• Sirius Medical Systems BV（荷兰）
• Molli Surgical Inc.（加拿大）
• Sterylab SRL (意大利)
• CP Medical（佐治亚州）
• MDL SRL（意大利）
• Biomedical Srl（意大利）
• Elucent Medical（美国）
• Vigeo srl（意大利）
• Medax 医疗器械（意大利）

SKU-68833